

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B

Name of entity				
Cycliq Group Limited - CYQ.AX				
ABN Quarter ended ("current quarter")				
47 119 749 647	31 December 2019			

nsolida	ted Statement of Cash Flows	Current quarter	Year to date
		31-Dec-19 \$A'000	\$A'000
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	*******
1.	Cash flows related to operating activities		
1.1	Receipts from customers	1,201	2,37
1.2	Payments for	-	
	(a) research and development	(4)	(
	(b) product manufacturing and operating costs	(532)	(1,43
	(c) advertising and marketing	(66)	(8
	(d) leased assets	(37)	(5
	(e) staff costs	(205)	(60
	(f) administration and corporate costs	(179)	(25
1.3	Dividends received (see note 3)		·
1.4	Interest received	-	
1.5	Interest and other costs of finance paid	(34)	(6
1.6	Income taxes paid	1 1	,
1.7	Government grants and tax incentives	40	
1.8	Other (provide details if material)	(182)	(30
	Material components of other operating activities	1	,
1.8a	Travel and accommodation expenses	(2)	(
1.8b	Other (multiple immaterial items)	(180)	(29
1.9	Net Operating Cash Flows	2	(39
2.	Cash flows related to investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	-	
	(b) businesses (see item 10)	-	
	(c) investments	-	
	(d) intellectual property	(3)	
	(e) other non-current assets	-	
2.2	Proceeds from disposal of:	-	
	(a) property, plant and equipment	-	
	(b) businesses (see item 10)	-	
	(c) investments	-	
	(d) intellectual property	-	
	(e) other non-current assets	-	
2.3	Cash flows from loans to other entities	_	
2.4	Dividends received (see note 3)	-	
2.5	Other (provide details if material)	_	
2.6	Net Investing Cash Flows	(3)	

Consolida	ted Statement of Cash Flows		
		Current quarter	
			Year to date
		31-Dec-19	
		\$A'000	\$A'000
3.	Cash flows related to financing activities		
3.1	Proceeds from issues of shares less share issue costs		
3.1	Froceeds from issues of strates less strate issue costs	-	741
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares,		(96)
	convertible notes or options]	(86)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(64)	(184)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net Financing Cash Flows	(64)	471
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	551	379
4.2	Net cash from / (used in) operating activities (item 1.9 above)	2	(391)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(3)	(3)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(64)	471
4.5	Effect of movement in exchange rates on cash held	(1)	29
4.6	Cash and cash equivalents at end of quarter	485	485

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank Balances	485	551
5.2	Call Deposits	-	-
5.3	Bank Overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	485	551

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	26
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-

	08-0
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2
Payment to	o Smallcap Corporate - an entity associated with Director Piers Lewis.

7.	Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1	Aggregate amount of payments to these parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

7.5	medade below any explanation necessary to understand the transactions included in items 7.1 and 7.2	
N/A - None		
1		

8.	Financing facilities available Add notes as necessary for an understanding of the position	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1	Loan facilities	2,000	642
8.2	Credit standby arrangements	-	-
8.3	Other (please specify)	-	-

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

facilities as well.				
cured Debt funding facility with privat	e investment firm, Partn	ers for Growth ('PFG) - Inte	erest rate @ 11.75%	

9.	Estimated cash outflows for next quarter	\$A'000
9.1	Research and development (expensed)	(2)
9.1a	Research and development (capital)	-
9.2	Product manufacturing and operating costs	(560)
9.3	Advertising and marketing	(45)
9.4	Leased assets	(19)
9.5	Staff costs	(294)
9.6	Administration and corporate costs	(82)
9.7	Other (provide details if material)	(89)
9.8	Total estimated cash outflows	(1,091)

Note: Please note per the ASX listing rules section 9 discloses only cash outflows forecast for the following quarter. These figures do not incorporate forecast cash inflows from sales, or any investing or financing activities

10.	Acquisition and disposals of business entities (items	Acquisitions	Disposals
	2.1(b) and 2.2(b) above		
10.1	Name of entity	N/A - none	N/A - none
10.2	Place of incorporation or registration	N/A - none	N/A - none
10.3	Consideration for acquisition or disposal	N/A - none	N/A - none
10.4	Total net assets / (liabilities)	N/A - none	N/A - none
10.5	Nature of business	N/A - none	N/A - none

Note: There were no acquisitions / disposals in the quarter.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Sign here: Date: Friday, 31 January 2020 (Director)

Print name: Piers Lewis